ACT Genomics Global

Home
ACT Genomics Global

Call Website

ACT Genomics is an internationally recognized award-winning cancer solution provider.

23/09/2026

Precision Oncology in Practice: A 60-Second Overview

Discover how comprehensive genomic analysis helps oncologists identify targeted therapy options and navigate complex treatment decisions.

📺 View the full video: https://smpl.is/an1pb

18/08/2026

It is our honor to be part of the Best of ASCO event taking place in Bangkok, Thailand. We really appreciate all the meaningful discussions on-site with attending physicians. Learning what's new from the ASCO event and the clinical insights from Thailand.

16/07/2026

It's BIO Asia Taiwan! Our booth is located at the BIO Taipei Pavilion (M632). Join us onsite for more discussion!
亞洲生技大展今日盛大開展，行動基因位於M632臺北生技館展出，歡迎蒞臨攤位共襄盛舉！

25/06/2026

When kidney disease remains “unknown,” the answer may still be hidden in the genome.

For early-onset CKD, unexplained kidney failure, persistent hematuria/proteinuria, suspected Alport syndrome, or familial kidney disease, ACTInherit Whole-Genome Sequencing (WGS) may help uncover molecular causes that narrower tests can miss.

Read the full article: https://smpl.is/al042

15/06/2026

In recognition of National Cancer Survivors Month, learn how next-generation sequencing (NGS) testing, cancer genomic testing, precision medicine, and long-term monitoring can support more informed cancer management from diagnosis to treatment planning and survivorship care. Read the full article, link: https://smpl.is/akp48

22/05/2026

A negative genetic test result does not always mean the genetic cause has been ruled out.

In Neurofibromatosis Type 1 (NF1), disease-causing variants may appear as small SNVs or indels, larger CNVs or structural variants, or variants located outside the usual coding regions, such as deep intronic variants.

In this article, ACT Genomics discusses how ACTInherit Whole Genome Sequencing (WGS) may support broader genomic analysis for complex or unresolved hereditary disease cases. Read the full article: https://smpl.is/ak16s

07/05/2026

International clinical guidelines and expert consensus are reshaping how genetic testing is considered in pediatric neurodevelopmental disorders.

For children with developmental delay, intellectual disability, autism spectrum disorder, congenital anomalies, or suspected hereditary disease, Whole Exome Sequencing (WES) and Whole Genome Sequencing (WGS) are increasingly recommended as early-line diagnostic tools in appropriate clinical scenarios.

In this article, ACT Genomics discusses how ACTExome and ACTInherit can support earlier molecular diagnosis, clearer clinical direction, and more informed long-term care planning. Read the full article: https://smpl.is/ajo1t

29/04/2026

When diabetes appears across generations, there may be an underlying hereditary cause that standard evaluation has not yet identified.

With ACTInherit Whole Genome Sequencing (WGS), this family’s underlying diagnosis was clarified as MODY—helping support a more informed direction for care.

Read the full article to learn how precision diagnosis may help change the course of care in familial diabetes: https://smpl.is/ajgi9

Address

Opening Hours

Monday	09:00 - 18:00
Tuesday	09:00 - 18:00
Wednesday	09:00 - 18:00
Thursday	09:00 - 18:00
Friday	09:00 - 18:00

Telephone

+6568162530

Website

http://www.actgenomics.com/

Alerts

Be the first to know and let us send you an email when ACT Genomics Global posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Want your business to be the top-listed engineering company?

Country:

City: